Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone versus eplerenone in worsening chronic heart failure with diabetes and/or chronic kidney disease
2012-002627-15Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF), left ventricular systolic dysfunction (LVSD), chronic kidney disease (CKD) and 1 more comparing Finerenone dose groups with Eplerenone comparator (2 arms). Primary endpoint: NT-proBNP response at Day 90. Started Mar 2013; status: completed.
02
Drugs
finerenoneeplerenone
03
Conditions
chronic heart failure (CHF)left ventricular systolic dysfunction (LVSD)chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002627-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002627-15.